Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease



Status:Not yet recruiting
Conditions:Skin Cancer, Cancer, High Blood Pressure (Hypertension), Peripheral Vascular Disease
Therapuetic Areas:Cardiology / Vascular Diseases, Oncology
Healthy:No
Age Range:40 - 75
Updated:4/6/2019
Start Date:April 2019
End Date:May 2020
Contact:Emily Banks, BS
Email:emily.s.banks@vumc.org
Phone:615-875-8949

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The purpose of this study is to understand the effect of vascular endothelial growth factor
tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination
treatment on blood pressure and blood vessel function.


Inclusion Criteria:

- Male or female, age 40 - 75 years old

- Diagnosis of cancer

- Receiving VEGF inhibitor treatment, ICI, or combination (VEGF inhibitor + ICI or
combination ICI) treatment

- Normal blood pressure or blood pressure treated to < 140/90 mm Hg with ≤ 2
antihypertensive medications

Exclusion Criteria:

- Presence of peripheral artery disease

- History of a heart attack within 1 year

- History of a stroke within 1 year

- Diabetes

- Life expectancy < 3 months

- Women who are pregnant

- Women who are nursing
We found this trial at
1
site
Vanderbilt University Medical Center
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Joshua Beckman, MD
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials